Laboratório de Pesquisa em Ciências da Saúde, Universidade Federal da Grande Dourados, Rodovia Dourados - Itahum, km 12, Cidade Universitária, Dourados, Mato Grosso do Sul, 79804970, Brazil.
World J Microbiol Biotechnol. 2023 Feb 1;39(3):86. doi: 10.1007/s11274-023-03530-6.
The spread of polymyxin-resistant Klebsiella pneumoniae strains represents an emerging health challenge, limiting treatment options for the patients. Thus, the development of new antimicrobials is an urgent requirement. Antimicrobial peptides (AMPs) are a large class of compounds that are part of innate immune response; these peptides are promising compounds in the field of antimicrobial resistance and are present in all organisms. The present review evaluated patents on antimicrobial peptides tested against polymyxin-resistant K. pneumoniae, available on Espacenet as of September 2022. A total of 1313 patents were examined and 1197 excluded as they were out of focus for this review; 104 patents of peptides tested against K. pneumoniae were included; of which only 14 were tested against polymyxin-resistant K. pneumoniae strains. The results indicated that all AMPs evaluated were in the experimental or pre-clinical phase; the clinical phase is pending. Furthermore, a few peptides were tested effectively against polymyxin-resistant K. pneumoniae. Although, the research and patent filing alone are not enough to develop a suitable antimicrobial therapy, they can represent good starting point upon which to develop new antimicrobials. More investment is required to push these pharmaceuticals through the stages of development to introduce them into the market.
多黏菌素耐药肺炎克雷伯菌菌株的传播代表了一个新出现的健康挑战，限制了患者的治疗选择。因此，开发新的抗菌药物是当务之急。抗菌肽 (AMPs) 是一大类化合物，是先天免疫反应的一部分; 这些肽在抗菌药物耐药性领域是很有前途的化合物，存在于所有生物体中。本综述评估了截至 2022 年 9 月在 Espacenet 上可获得的针对多黏菌素耐药肺炎克雷伯菌的抗菌肽专利。共检查了 1313 项专利，其中 1197 项因与本综述无关而被排除在外; 共纳入了 104 种针对肺炎克雷伯菌的肽进行了测试; 其中只有 14 种针对多黏菌素耐药肺炎克雷伯菌菌株进行了测试。结果表明，所有评估的 AMPs 均处于实验或临床前阶段; 临床阶段尚未进行。此外，有几种肽对多黏菌素耐药肺炎克雷伯菌的有效测试。尽管如此，研究和专利申请本身不足以开发出合适的抗菌治疗方法，但它们可以作为开发新抗菌药物的良好起点。需要更多的投资来推动这些药物通过开发阶段，将它们推向市场。
